# A case report of plaque psoriasis comorbid with hidradenitis suppurativa, hepatitis B, and colorectal cancer treated with xeligekimab

## TL;DR

A 43-year-old man with multiple chronic conditions, including psoriasis and cancer, showed significant improvement after 28 weeks of treatment with xeligekimab, a new IL-17A inhibitor.

## Contribution

This case report demonstrates the potential efficacy and safety of xeligekimab in treating complex multimorbid inflammatory conditions.

## Key findings

- Xeligekimab treatment led to significant improvement in psoriasis and hidradenitis suppurativa symptoms over 28 weeks.
- No progression of colorectal cancer or hepatitis B was observed during treatment.
- Quality of life and clinical indicators, such as PASI and DLQI, showed substantial improvement.

## Abstract

Psoriasis and hidradenitis suppurativa are chronic inflammatory skin diseases with common pathogenesis, such as the involvement of IL-17A, which also plays an essential role in the development and metastasis of colorectal cancer. Xeligekimab, a novel IL-17A inhibitor, offers a targeted therapeutic approach for these conditions.

A 43-year-old male presented with a 12-year history of plaque psoriasis and hidradenitis suppurativa. Previous treatment with topical corticosteroids, Calcipotriol Betamethasone Ointment and acitretin provided poor control of psoriasis, resulting in significant quality-of-life impairment. His comorbidities include chronic hepatitis B managed with 10-year antiviral therapy and metastatic colorectal cancer treated with synchronous resection of liver metastases during primary tumor surgery 6 years ago (no recurrence).

After 28 weeks of xeligekimab treatment, the patient experienced significant improvement in symptoms and skin lesions. The evaluation indicators demonstrated a sustained decline: PASI decreased from 51 to 0.8, BSA from 87% to 6%, DLQI from 20 to 1, and Hurley staging improved to Grade I. During follow-up, imaging and tumor marker testing revealed no signs of tumor and hepatitis B progression.

Xeligekimab demonstrated significant efficacy and acceptable safety over 28 weeks in this complex case of psoriasis with concurrent hidradenitis suppurativa, chronic hepatitis B, and metastatic colorectal cancer. Extended follow-up is ongoing to evaluate long-term outcomes, while larger prospective studies are warranted to validate biologic therapy for such multimorbid presentations.